Add BrightSurf on Google Email

“Third era” of GPCR drug discovery could accelerate precision medicine development

Researchers at the Center for Genomic Regulation developed a new method to identify new druggable sites on GPCRs, a family of proteins targeted by one in three drugs. This approach enables the creation of detailed functional maps, leading to more precise control of cellular response and reduced unwanted side effects.

SourceCenter for Genomic Regulation·JournalNature Structural & Molecular Biology·DateNov 11, 2026

Are women more susceptible to PTSD?

Researchers at the University of Cincinnati found a potential biomarker for PTSD susceptibility in female animal models, suggesting a link to stress hormone patterns. The study suggests that a simple stress provocation test could serve as a clinical biomarker for PTSD risk and point toward early interventions. The findings raise the po...

SourceUniversity of Cincinnati·JournalFrontiers in Cellular Neuroscience·TypeExperimental study·DateNov 10, 2026

New biomarker improves detection of date-rape drug

A promising biomarker, GHB-pentose, has been discovered to detect GHB in urine for up to three days after intake, providing a longer detection window. The biomarker has also been found in deceased individuals, potentially helping investigators determine if GHB was ingested before death.

SourceUniversity of Zurich·JournalDrug Testing and Analysis·TypeRandomized controlled/clinical trial·DateNov 10, 2026

FSU chemists develop light-powered method to resurrect ‘dead-end’ compounds for drug discovery

Researchers have developed a light-powered chemical reaction to transform 'dead-end' sulfonamide compounds into useful building blocks for future drug discoveries. This method, using photochemical reactions, can revive these compounds, allowing researchers to create new medicines while preserving their existing features.

SourceFlorida State University·JournalJournal of the American Chemical Society·DateNov 6, 2026

FINDing new drug leads faster with DNA nanotechnology

Researchers developed FIND, a drug discovery platform that uses DNA nanoswitches to select drug candidates based on their effects on protein-protein interactions. The platform identifies molecules that modulate binding interactions between two proteins, introducing unprecedented functionality and efficiency into drug screening.

SourceWyss Institute for Biologically Inspired Engineering at Harvard·JournalScience·TypeExperimental study·DateNov 5, 2026

KAIST uses wireless neural chip to track brain changes in real time after Alzheimer’s drug administration

Researchers at KAIST have developed an implantable neural chip that integrates neurotransmitter sensing, light stimulation, and wireless monitoring. The chip was tested in miniature pigs and showed an increase in neurotransmitter signal following drug administration, followed by a gradual return to baseline.

Metabolite-inspired compounds show promise for ulcerative colitis drug discovery, study finds

Researchers at Georgia State University discovered two metabolite-inspired compounds, MLY2 and MLY8, with enhanced anti-inflammatory activity in experimental ulcerative colitis. These compounds showed promise for treating the chronic inflammatory disease, offering an underexplored drug discovery opportunity.

SourceGeorgia State University·JournalInternational Journal of Molecular Sciences·TypeExperimental study·DateOct 2, 2026

KAIST identifies a “hidden amplification switch” in lymphangiogenic signaling, with implications for lymphedema and cancer metastasis

Researchers at KAIST have discovered that VEGF-C brings two VEGFR-3 receptors together, leading to clustering and amplification of lymphangiogenic signaling. This process may provide new strategies for treating related diseases such as lymphedema and cancer metastasis.

Cancer cachexia: How a tumor protein drives wasting in the body

Researchers at Helmholtz Munich have identified a tumor protein called ADAMTSL4 as a key driver of cancer cachexia, a wasting process that affects muscle and fat tissue. The protein locally activates the TGF-β signaling pathway, triggering a catabolic program that promotes muscle and fat breakdown.

Engineered human neurons rebuild damaged spinal cord circuits

Scientists at Gladstone Institutes have developed a regenerative treatment using stem cell-derived spinal interneurons to repair damaged neural networks in rats. The new cells not only survived and formed connections with the animals' own neural circuits but also improved breathing-related motor function after transplantation.

SourceGladstone Institutes·JournalScience Translational Medicine·DateAug 5, 2026

Newly discovered mitochondrial microprotein linked to Type 2 diabetes — and shows early promise as a precision treatment

A study at USC discovers a common genetic variant in Indigenous American populations that silences the microprotein MENTSH, restoring it improves insulin signaling and blocks diet-induced weight gain. MENTSH-based therapies could offer a precision-medicine approach to Type 2 diabetes.

SourceUniversity of Southern California·JournalTheranostics·TypeObservational study·DateJul 30, 2026

College of Pharmacy, Pusan National University study explores rare atom-containing natural products and their biomedical potential

A review study reveals diverse metabolite families containing atypical atoms, including fluorine, selenium, arsenic, and boron, with distinct biological functions and properties. These elements shape natural products with structural and functional versatility, paving ways toward sustainable biotechnologies.

SourcePusan National University·JournalNatural Product Reports·TypeLiterature review·DateJul 21, 2026

Progress & accountability in modern life sciences in SLAS Technology Vol. 38

This volume of SLAS Technology highlights novel laboratory technologies, open-source software, and disease-specific tools for advancing life sciences research and development. The journal emphasizes the importance of education, knowledge exchange, and global community building to drive innovation in biomedical research.

Human-safe drug repairs DNA in a mouse model of Alzheimer's

Scientists at King's College London have developed a human-safe drug that repairs DNA breaks and reduces inflammation in a mouse model of Alzheimer's disease. This approach targets multiple features of the disease simultaneously, providing a broader therapeutic strategy than previous approaches focused on individual disease hallmarks.

SourceKing's College London·JournalFEBS Open Bio·TypeExperimental study·DateJul 8, 2026

Drug candidate treats severe fatty liver disease by protecting the gut in animal models

Researchers discovered a potential drug developed at Michigan Medicine reverses metabolic dysfunction-associated steatohepatitis (MASH) in animal models by disrupting the disease-driving pathway that links the gut and liver. DT-109 improved gut health, reducing inflammation in livers of nonhuman primates.

SourceMichigan Medicine - University of Michigan·JournalJournal of Clinical Investigation·TypeExperimental study·DateJul 7, 2026

The language of proteins

BetaDescribe, an AI system, converts protein sequences into detailed textual descriptions of their functions and characteristics. The technology helps bridge the gap between characterized and existing proteins in nature, enabling researchers to rapidly generate evidence-based hypotheses regarding unknown proteins.

SourceTechnion-Israel Institute of Technology·JournalProceedings of the National Academy of Sciences·TypeComputational simulation/modeling·DateJul 6, 2026